Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079431 | 1.00 | NPC1 (0.55) | NPC1GAACYP1A2AKR1C3AKR1C2 | |
| SCHEMBL14668359 | 0.85 | MAPT (0.49) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL9847272 | 0.81 | NPC1 (0.47) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL2728552 | 0.80 | CYP1A2 (0.47) | NPC1GAACYP1A2CYP2C19MAPT | |
| SCHEMBL2728549 | 0.80 | CYP1A2 (0.47) | NPC1GAACYP1A2CYP2C19MAPT | |
| SCHEMBL2732414 | 0.78 | MAPT (0.48) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL16814417 | 0.78 | CYP2C19 (0.51) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL16814418 | 0.78 | CYP2C19 (0.51) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL1645440 | 0.77 | NPC1 (0.42) | NPC1GAACYP1A2CYP2C19PKM | |
| SCHEMBL31718130 | 0.76 | AKR1C3 (0.62) | NPC1AKR1C3AKR1C2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014850-A | Prudelamine intermediate, synthesis method thereof and method for synthesizing prasulamine from intermediate | 山东汇海医药化工有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | NPC1 4819/4885GAA 3898/4885CYP1A2 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.